ArticleJournal of oncology2022
circSYPL1 Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma via the Upregulation of EZH2 Expression by Competing with hsa-miR-506-3p.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Treating human cancer by targeting EZH2.Genes & diseases · 2025Review
- Pan-cancer analysis of Methyltransferase-like 16 (METTL16) and validated in colorectal cancer.Aging · 2025Article
- Review
- Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches.Pharmaceutics · 2023Review
- An anoikis-related gene signature predicts prognosis and reveals immune infiltration in hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Bone-Metabolism-Related Serum microRNAs to Diagnose Osteoporosis in Middle-Aged and Elderly Women.Diagnostics (Basel, Switzerland) · 2022Article
- circRNA: A New Biomarker and Therapeutic Target for Esophageal Cancer.Biomedicines · 2022Review
- A cellular senescence-related genes model allows for prognosis and treatment stratification of hepatocellular carcinoma: A bioinformatics analysis and experimental verification.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Circular RNAs (circRNAs) and microRNAs are crucial for progressing of hepatocellular carcinoma (HCC). Nonetheless, the function or mechanisms of a newly discovered circRNA, circSYPL1, as well as miR-506-3p, in the progression of HCC are mostly unexplained. The purpose of this research was to determine the mechanisms by which circSYPL1 and miR-506-3p regulate the malignant features of HCC. Methods: The expression level of circSYPL1 was indeed detected using real-time PCR in HCC cell lines, primary as well as metastatic cancers. To assess the functionality of circSYPL1 upregulation and knockdown, we used proliferation and apoptosis, in addition to migration assays, as well as tumor xenograft and lung metastasis assays. The mechanisms of competing endogenous RNAs with circSYPL1/miR-506-3p/EZH2 were investigated using luciferase as well as RNA pull-down experiments. Lastly, cell proliferation and migration, in addition to tumor xenograft tests, were used to validate the biological significance of the circSYPL1/miR-506-3p/EZH2 signaling axis through overexpression or otherwise silencing. Results: circSYPL1 expression was significantly upregulated in HCC cell lines, in addition to primary and metastatic tumors of patients with HCC. Additionally, it may promote HCC initiation, development as well as progression. By knocking down circSYPL1 siRNA, we were able to drastically decrease the aggressiveness of HCC cells. circSYPL1 sponged miR-506-3p to boost EZH2 expression levels, as indicated by luciferase and RNA pull-down assays. Furthermore, circSYPL1 overexpression could upregulate EZH2 expression, while miR-506-3p mimics or EZH2 shRNAs could reverse the circSYPL1-induced malignancy of HCC cells. Conclusion: On a mechanistic level, circSYPL1 can interact with miR-506-3p in a competitive manner to upregulate EZH2, hence increasing the aggressiveness of tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.